NCT05165433View on ClinicalTrials.gov

Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Epithelial TumorMetastatic Cancer
Interventions
BIOLOGICAL

NG-350A plus Pembrolizumab

Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion

Trial Locations (7)

19104

Perelman Center of Advanced Medicine, Philadelphia

34747

Moffitt-Advent Health Clinical Research Unit, Celebration

77030

MD Anderson Cancer Center, Houston

90404

Providence Medical Foundation, Santa Monica

UCLA, Santa Monica

L7 8YA

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

OX3 7LE

Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford

Sponsors

Lead Sponsor

Akamis Bio
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Akamis Bio

INDUSTRY

NCT05165433 - Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) | Biotech Hunter | Biotech Hunter